Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RFL – Rafael Holdings Inc

Rafael Holdings, Inc.
RFL
$1.24
Name : Rafael Holdings, Inc.
Sector : Real Estate
Industry: Real Estate Services
Mark. Cap: $63,936,944.00
EPSttm : -1.04
finviz dynamic chart for RFL
Rafael Holdings, Inc.
$1.24
1.23%
$0.015

Float Short %

0.18

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.24

Target Price

Analyst Recom

Performance Q

-21.29

Relative Volume

2.75

Beta

0.69

Ticker: RFL




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20RFL1.390.010.001220
2025-10-21RFL1.370.010.001309
2025-10-22RFL1.40.010.001359
2025-10-23RFL1.360.010.001359
2025-10-24RFL1.3550.010.001359
2025-10-27RFL1.350.010.001358
2025-10-28RFL1.340.010.001359
2025-10-29RFL1.350.010.001360
2025-10-30RFL1.340.010.001360
2025-10-31RFL1.360.010.001360
2025-11-03RFL1.3480.010.001360
2025-11-04RFL1.330.010.001360
2025-11-05RFL1.3390.010.001360
2025-11-06RFL1.298N/AN/A0
2025-11-07RFL1.310.010.041361
2025-11-10RFL1.30.010.001348
2025-11-11RFL1.2880.010.001348
2025-11-12RFL1.2750.010.001348
2025-11-13RFL1.30.010.001352
2025-11-14RFL1.220.010.001352
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20RFL1.39- - -
2025-10-21RFL1.37- - -
2025-10-22RFL1.38- - -
2025-10-23RFL1.38- - -
2025-10-24RFL1.36- - -
2025-10-27RFL1.36- - -
2025-10-28RFL1.34- - -
2025-10-29RFL1.35- - -
2025-10-30RFL1.35- - -
2025-10-31RFL1.36- - -
2025-11-03RFL1.34- - -
2025-11-04RFL1.33- - -
2025-11-05RFL1.34- - -
2025-11-06RFL1.30- - -
2025-11-07RFL1.29- - -
2025-11-10RFL1.30- - -
2025-11-11RFL1.27- - -
2025-11-12RFL1.27- - -
2025-11-13RFL1.27- - -
2025-11-14RFL1.24- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20RFL126.9210.560.54
2025-10-21RFL126.9210.560.54
2025-10-22RFL126.9010.560.54
2025-10-23RFL126.9010.560.54
2025-10-24RFL126.9010.560.54
2025-10-27RFL126.8810.300.49
2025-10-28RFL126.8810.300.49
2025-10-29RFL126.8810.300.49
2025-10-30RFL126.8810.300.49
2025-10-31RFL126.8810.300.49
2025-11-03RFL61.106.330.33
2025-11-04RFL61.456.330.33
2025-11-05RFL61.446.330.33
2025-11-06RFL61.456.330.33
2025-11-07RFL61.456.330.33
2025-11-10RFL61.456.160.33
2025-11-11RFL61.456.160.33
2025-11-12RFL61.446.160.36
2025-11-13RFL61.456.160.36
2025-11-14RFL61.456.160.18
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

61.45

Institutional Transactions

6.16

Beta

0.69

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

44

Growth Score

42

Sentiment Score

44

Actual DrawDown %

98.1

Max Drawdown 5-Year %

-98

Target Price

P/E

Forward P/E

PEG

P/S

68.67

P/B

0.67

P/Free Cash Flow

EPS

-1.03

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3328.24

Relative Volume

2.75

Return on Equity vs Sector %

-37.9

Return on Equity vs Industry %

-38.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Rafael Holdings, Inc.
Sector: Real Estate
Industry: Real Estate Services
Employees: 21
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
stock quote shares RFL – Rafael Holdings Inc Stock Price stock today
news today RFL – Rafael Holdings Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch RFL – Rafael Holdings Inc yahoo finance google finance
stock history RFL – Rafael Holdings Inc invest stock market
stock prices RFL premarket after hours
ticker RFL fair value insiders trading